National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Tildrakizumab (Ilumetri®). HTA ID: 19029

Tildrakizumab (Ilumetri®) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 30/07/2019
Rapid review completed 28/08/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tildrakizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.
Full pharmacoeconomic assessment commissioned by HSE 19/05/2020
Pre-submission consultation with Applicant 08/02/2021
Initial submission received from Applicant 04/05/2021
Preliminary Review sent to Applicant 20/07/2021
NCPE assessment re-commenced 23/08/2021
Factual accuracy check sent to Applicant 15/10/2021
NCPE assessment re-commenced 03/11/2021
NCPE assessment completed 25/11/2021
NCPE assessment outcome The NCPE recommends that tildrakizumab (Ilumetri®), for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy and who have failed treatment with non-biologic therapies and first-line biologic treatment with adalimumab, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.